Cancel
Executive
TEAM
Paradigm’s leadership team is highly experienced in scientific discovery, regulatory affairs, drug development, clinical trials, finance, and investor relations, as well as licensing and commercialisation.
They are genuinely ‘experts in uncovering the real value of a molecule’.
Sharing a belief in transforming medicine and its potential to open up new treatment options for people around the globe, the team’s strategic plan centres upon ensuring Paradigm grows and fosters the knowledge, talent, experience and creativity necessary for long term success.
They lead by example in shaping a company culture that supports Paradigm’s Purpose and Vision.
PAUL RENNIE
MANAGING DIRECTOR
Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.
PAUL RENNIE
MANAGING DIRECTOR
Mr Rennie is recognised as a leading authority in drug development and has been involved in a number of pre-clinical and clinical trial programs over his accomplished career. He was the inaugural COO of Mesoblast and most recently as Executive VP, New Product Development at Mesoblast Ltd. Mr. Rennie has extensive experience in commercialising Intellectual Property.
Dr Donna Skerrett
Chief Medical Officer
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine,
cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a
stem cell development company, from 2011-19; Dir. Transfusion Medicine &
Cellular Therapy at Weill Cornell Medical Center, NY from 2004-11; and Ass.
Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital.
She has chaired the NY State Governor’s Council on Blood and Transfusion
Service and served on the Board of Directors of the Fox Chase Cancer Center.
She currently serves in an advisory role on the Board of Visitors for the Lewis
Katz School of Medicine of Temple University.
Dr Donna Skerrett
Chief Medical Officer
Dr. Skerrett, has more than 30 years’ experience in transfusion medicine, cellular therapy, and regenerative medicine. She was the CMO of Mesoblast, a stem cell development company, from 2011-19; Dir. Transfusion Medicine & Cellular Therapy at Weill Cornell Medical Center, NY from 2004-11; and Ass. Dir. Transfusion Medicine at Columbia University’s NY-Presbyterian Hospital. She has chaired the NY State Governor’s Council on Blood and Transfusion Service and served on the Board of Directors of the Fox Chase Cancer Center. She currently serves in an advisory role on the Board of Visitors for the Lewis Katz School of Medicine of Temple University.
Justin Cahill
Chief Financial Officer
Mr Cahill has over 20 years’ experience in strategic finance roles across a
broad spectrum of industries and global organisations. In one of his more
recent and prominent roles, Justin spent 9 years at CSL, including 5 years as
Divisional CFO of CSL Plasma. Justin is a CPA and holds a Master’s in
Accounting. Experienced in global operations expansion, Mr Cahill oversees
the financial management of Paradigm’s growing portfolio and increasingly
complex activities.
Justin Cahill
Chief Financial Officer
Mr Cahill has over 20 years’ experience in strategic finance roles across a broad spectrum of industries and global organisations. In one of his more recent and prominent roles, Justin spent 9 years at CSL, including 5 years as Divisional CFO of CSL Plasma. Justin is a CPA and holds a Master’s in Accounting. Experienced in global operations expansion, Mr Cahill oversees the financial management of Paradigm’s growing portfolio and increasingly complex activities.
Dr Ravi Krishnan
Chief Scientific Officer
Dr Krishnan is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell
therapy. He has had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic
properties.
Dr Ravi Krishnan
Chief Scientific Officer
Dr Krishnan is a basic scientist with a long-standing interest and experience in experimental pathology, transplantation immunology, gene and stem cell therapy. He has had significant experience in investigating novel compounds with immune modulatory effects, anti-inflammatory and anti-angiogenic properties.
Simon White
Director of Investor Relations
Mr White brings a unique set of skills to his role. His career to date combines
experience in equity capital markets and the financial services sector (gained
as Corporate Advisory at DELCOR, a Melbourne based Family Office, and
Institutional Sales at Sequoia Wealth Management) with time as a high-
performance athlete (he was a professional footballer for the AFL team,
Carlton, for 8 years). His team-orientated approach and networking skills are
highly valued.
Simon White
Director of Investor Relations
Mr White brings a unique set of skills to his role. His career to date combines experience in equity capital markets and the financial services sector (gained as Corporate Advisory at DELCOR, a Melbourne based Family Office, and Institutional Sales at Sequoia Wealth Management) with time as a high- performance athlete (he was a professional footballer for the AFL team, Carlton, for 8 years). His team-orientated approach and networking skills are highly valued.
